2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2200058224 | 2022-05-01 | 2022-04-03 | The treatment of primidone for bulbar dysfunction in amyotrophic lateral sclerosis: A randomized, double-blind, cross-over controlled clinical trial | The treatment of primidone for bulbar dysfunction in amyotrophic lateral sclerosis: A randomized, double-blind, cross-over controlled clinical trial | amyotrophic lateral sclerosis | Group A:phase I: primidone 60 mg/d; Wash-out period: no intervention; phase II: placebo control;Group B:phase I: placebo control; Wash-out period: no intervention; phase II: primidone 60 mg/d; | The First People's Hospital of Yichang | NULL | Pending | 18 | Both | Group A:50;Group B:50; | Phase 2 | China |